Promising Advances in HER2-Negative Breast Cancer Treatment: Alphamab Oncology’s JSKN016
Alphamab Oncology is making significant strides in the oncology field with its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC), JSKN016. The company has announced that results from a Phase I clinical study will be showcased at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. This research focuses on treating HER2-negative locally advanced or metastatic breast cancer, a challenging area in cancer therapy.
Study Overview
The Phase I clinical study, designated JSKN016-101, is a dose-escalation and dose-expansion trial conducted in China. It enrolls patients with advanced solid tumors who receive monotherapy with JSKN016. During the ASCO meeting, the analytical findings from the HER2-negative breast cancer cohort will be highlighted. Early results indicate that JSKN016 shows substantial efficacy and a superior safety profile, particularly in patients with late-stage breast cancer. This progress supports further exploration of JSKN016, both as a standalone treatment and in combination with chemotherapy, immunotherapy, and targeted therapies for frontline and perioperative settings.
Key Presentation Details
The details of the presentation are as follows:
Title: JSKN016, a First-in-Class Anti-TROP2/HER3 Bispecific Antibody-Drug Conjugate (ADC) in Patients with HER2-Negative Locally Advanced or Metastatic Breast Cancer: Results from a Phase I Study
Principal Investigator: Professor Herui Yao, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Presentation Time: June 1, 2026, 1:30-4:30 PM CDT
Mechanism of Action
JSKN016 is designed using proprietary technologies that enable targeted therapy against TROP2 and HER3 receptors on tumor cells. The ADC employs site-specific glycosylation, resulting in a homogeneous and stable formulation with a drug-to-antibody ratio (DAR) of 4. By binding to these receptors, JSKN016 effectively inhibits tumor signaling pathways and releases topoisomerase I inhibitors, which contribute to its powerful antitumor activity. The glycan conjugation technology enhances the stability of the ADC while minimizing off-target toxicity, making it a promising candidate for clinical use.
Clinical Efficacy and Safety Profile
Preliminary clinical studies involving JSKN016 have shown encouraging antitumor activity and a favorable safety profile across various solid tumors, including advanced triple-negative breast cancer (TNBC). The ongoing Phase III clinical trial specifically targeting TNBC aims to further validate the effectiveness of JSKN016 in this challenging patient population. The positive findings from these studies underscore the potential of JSKN016 as a viable treatment option for patients who have exhausted other therapies.
Innovations in Oncology
Alphamab Oncology, listed under stock code 9966.HK, is an innovative biopharmaceutical company that focuses on oncology. The organization leverages a range of proprietary platforms, including single-domain antibodies and bispecific antibodies, to create a competitive pipeline of advanced therapeutic candidates, particularly in the ADC space. The company is committed to addressing unmet clinical needs in cancer treatment and aims to provide safe and effective therapies worldwide.
Market Approvals and Future Directions
Among its achievements, Alphamab has received market approval for Envafolimab (KN035), which is the first subcutaneously injected PD-(L)1 inhibitor available globally. This innovation aims to improve patient convenience and access to cancer treatment. Furthermore, the National Medical Products Administration (NMPA) is currently reviewing a new drug application for KN026, a HER2 bispecific antibody designed for HER2-positive gastric cancer.
With five bispecific ADC candidates now in clinical stages and advancements in next-generation ADC pipelines including dual-payload ADCs, Alphamab is positioning itself as a leader in the oncology sector. Strategic partnerships with organizations such as CSPC, ArriVent, and Glenmark further bolster its ability to develop and deliver effective cancer therapies.
Commitment to Cancer Care
Alphamab Oncology remains steadfast in its mission to transform cancer treatment. The company aspires to make cancer more manageable and curable by developing innovative solutions that cater to unmet clinical needs. By prioritizing the creation of effective and safe anti-tumor drugs, Alphamab aims to enhance patient quality of life and contribute to long-term survival outcomes.
Key Takeaways
- JSKN016 is a bispecific ADC targeting TROP2 and HER3 for HER2-negative breast cancer.
- Promising Phase I trial results will be presented at ASCO 2026.
- The technology behind JSKN016 enhances stability and minimizes toxicity.
- Alphamab is advancing multiple candidates in its oncology pipeline.
- The company is dedicated to addressing significant clinical needs in cancer treatment.
In conclusion, Alphamab Oncology’s commitment to innovation and patient care shines through its development of JSKN016. As they prepare to present their findings at ASCO, the future looks promising for new treatment avenues in HER2-negative breast cancer, offering hope to patients and families affected by this disease.
Read more → www.manilatimes.net